ProShare Advisors
AZN icon

ProShare Advisors’s AstraZeneca AZN Stock Holding History

ProShare Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-466,312
Closed -$85.7M – 1882
2025
Q4 		$85.7M Buy
466,312
+138,882
+42% +$24.4M 0.15% 145
2025
Q3 		$50.2M Sell
327,430
-89,401
-21% -$13.5M 0.11% 162
2025
Q2 		$58.3M Buy
416,831
+24,128
+6% +$3.38M 0.12% 162
2025
Q1 		$57.7M Buy
392,703
+48,612
+14% +$7.03M 0.13% 153
2024
Q4 		$45.1M Buy
344,091
+53,861
+19% +$7.54M 0.1% 166
2024
Q3 		$45.2M Buy
290,230
+25,441
+10% +$4.11M 0.11% 154
2024
Q2 		$41.3M Sell
264,789
-39,598
-13% -$5.96M 0.11% 150
2024
Q1 		$41.2M Buy
304,387
+60,714
+25% +$8.04M 0.11% 160
2023
Q4 		$32.8M Sell
243,673
-44,862
-16% -$5.83M 0.1% 194
2023
Q3 		$39.1M Buy
288,535
+39,376
+16% +$5.38M 0.12% 155
2023
Q2 		$35.7M Sell
249,159
-22,840
-8% -$3.36M 0.1% 173
2023
Q1 		$37.8M Buy
271,999
+16,275
+6% +$2.19M 0.12% 161
2022
Q4 		$34.7M Sell
255,724
-29,399
-10% -$3.69M 0.12% 171
2022
Q3 		$31.3M Sell
285,123
-47,580
-14% -$6.04M 0.12% 147
2022
Q2 		$44M Sell
332,703
-152,968
-31% -$20.1M 0.15% 135
2022
Q1 		$64.4M Buy
485,671
+442,974
+1,037% +$53.1M 0.14% 151
2021
Q4 		$4.97M Buy
42,697
+9,336
+28% +$1.1M 0.01% 569
2021
Q3 		$4.01M Buy
33,361
+1,315
+4% +$153K 0.01% 551
2021
Q2 		$3.84M Buy
32,046
+251
+0.8% +$27.5K 0.01% 552
2021
Q1 		$3.16M Sell
31,795
-5,948
-16% -$598K 0.01% 563
2020
Q4 		$3.77M Buy
+37,743
New +$4M 0.01% 489

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Asset Management
Vanguard Asset Management London, Ec4n 8af $148B AUM

ProShare Advisors's AZN Position: Q1 2026 in Review

ProShare Advisors sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 466,312 shares — an estimated $85.7M sold.

ProShare Advisors first reported a position in AZN in Q4 2020 and held it in 21 quarters. The position peaked at $85.7M in Q4 2025. 1,386 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • ProShare Advisors reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
  • ProShare Advisors sold 466,312 AstraZeneca shares in Q1 2026, an estimated $85.7M.
  • ProShare Advisors first reported a position in AstraZeneca in Q4 2020 and held it in 21 quarters.
  • ProShare Advisors's AstraZeneca position peaked at $85.7M in Q4 2025.
  • 1,386 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.